Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/jspui/handle/123456789/15748
Title: Novel insights to enhance therapeutics with acyclovir in the management of herpes simplex encephalitis.
Authors: Assis, Maria Silvia Gurgel
Pedrosa, Taciane Cristina Fernandes
Moraes, Fernanda Segurasse de
Caldeira, Tamires Guedes
Pereira, Gislaine Ribeiro
Souza, Jacqueline de
Ruela, Andre Luís Morais
Keywords: Absorption enhancer
Bioavailability
Clinical trial
Drug delivery system
Drug targeting
Issue Date: 2021
Citation: ASSIS, M. S. G. et al. Novel insights to enhance therapeutics with acyclovir in the management of herpes simplex encephalitis. Journal of Pharmaceutical Sciences, v. 110, p. 1557-1571, 2021. Disponível em: <https://www.sciencedirect.com/science/article/abs/pii/S0022354921000083>. Acesso em: 11 out. 2022.
Abstract: Acyclovir is an antiviral drug poorly absorbed in the gastrointestinal tract due to its hydrophilicity, with low oral bioavailability (~20%). Although acyclovir is prescribed in the management of herpes simplex encephalitis (HSE), the disease has a poor prognosis, particularly if the treatment is delayed, reaching mortality rates of 70% if left untreated. Thus, high acyclovir doses are administered by intravenous (IV) infusion, usually at a dosage of 10 mg kg1 8-hourly in adults with normal renal function. However, the mortality related to HSE treated with acyclovir remains high (~20%) and permanent sequelae are commonly reported after 1 year (~50%). This review analyzed clinical trials following IV acyclovir administration. Novel insights aiming to improve drug bioavailability were reviewed, including acyclovir or its prodrugs, leading to the systemic distribution of the drug or drug targeting. Much research effort has been made to improve antiviral therapy, searching for delivery systems increasing acyclovir bioavailability by non-invasive pathways, such as oral and nasal pathways, or parenterally administered nanotechnology-based systems leading to drug targeting. Nanocarriers administered by non-invasive pathways represent feasible alternatives to treat HSE, even though not be industrially manufactured yet.
URI: http://www.repositorio.ufop.br/jspui/handle/123456789/15748
metadata.dc.identifier.uri2: https://www.sciencedirect.com/science/article/abs/pii/S0022354921000083
metadata.dc.identifier.doi: https://doi.org/10.1016/j.xphs.2021.01.003
ISSN: 0022-3549
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_NovelInsigtsEnhace.pdf
  Restricted Access
1,86 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.